Patents by Inventor Lorelei A. Mucci

Lorelei A. Mucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for screening and identifying clinically aggressive prostate cancer
    Patent number: 11971411
    Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 30, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Curtis Huttenhower, Travis Gerke, Christopher Sweeney, Lorelei Mucci, Gwo-Sho Mary Lee, Daniela Bornigen, Xiaodong Wang, Svitlana Tyekucheva, Kristina Jordahl
  • Compositions and methods for diagnosing prostate cancer using a gene expression signature
    Patent number: 10900086
    Abstract: The present invention relates to compositions and methods and for the diagnosis, prognosis, and treatment of prostate cancer. The invention is based upon the identification of a gene expression signature that predicts the likelihood that prostate cancer will metastasize. Provided is a method of determining whether prostate cancer in a subject will metastasize. Also provided are compositions comprising a prostate cancer-associated gene. Also provided are kits comprising a package with a prostate cancer-associated gene.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 26, 2021
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michaela Bowden, Svitlana Tyekucheva, Massimo Loda, Lorelei Mucci
  • COMPOSITIONS AND METHODS FOR SCREENING AND IDENTIFYING CLINICALLY AGGRESSIVE PROSTATE CANCER
    Publication number: 20200041515
    Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
    Type: Application
    Filed: January 20, 2017
    Publication date: February 6, 2020
    Inventors: CURTIS HUTTENHOWER, TRAVIS GERKE, CHRISTOPHER SWEENEY, LORELEI MUCCI, GWO-SHO MARY LEE, DANIELA BORNIGEN, XIAODONG WANG, SVITLANA TYEKUCHEVA, KRISTINA JORDAHL
  • Predicting And Treating Prostate Cancer
    Publication number: 20120121618
    Abstract: The disclosure features methods and compositions for determining whether a male subject has, or is at an increased risk of developing, an aggressive form of prostate cancer. The disclosure also features methods for adjusting a treatment regimen (e.g., discontinuing a therapy comprising an antioxidant) or administering a therapy that does not contain an antioxidant for a male subject in view of one or both of an MnSOD2 genotype status and an elevated level of an antioxidant in a biological sample obtained from the male subject. Also featured are methods for reducing superoxide levels in a subject based on one or both of an MnSOD2 genotype status and an elevated level of an antioxidant in a biological sample obtained from the male subject.
    Type: Application
    Filed: February 12, 2010
    Publication date: May 17, 2012
    Inventors: Philip W. Kantoff, William K. Oh, June M. Chan, Wanling Xie, Miyako Abe, Lorelei A. Mucci